

## International experts join Microba Life Sciences inaugural IBD Advisory Panel

28 June 2021 | News

**Aim to accelerate patient access to breakthrough new microbiome-based therapies to improve the standard of care.**



Precision microbiome science company, Microba Life Sciences, has appointed three respected key opinion leaders in Inflammatory Bowel Disease (IBD) to their IBD Advisory Panel to translate research into clinical outcomes for IBD sufferers.

Professors from Mount Sinai Doctors in the United States, Professor Jean-Frederic Colombel, MD and University of Miami Health System, Professor Maria Teresa Abreu will join with Australia's own Associate Professor Jake Begun from Mater Health.

The trio will guide the company's therapeutic programs to address major unmet clinical needs associated with IBD treatment.

The three renowned gastroenterology experts will provide insight to Microba's research team on therapeutic clinical needs, translation of therapeutic candidates into and through the clinic.

The aim is to accelerate patient access to breakthrough new microbiome-based therapies to improve the standard of care.

**Associate Professor Jakob Begun** is a world-renowned leader in clinical trials and research, specializing in the delivery of care and the effectiveness of current therapies. He is joined by US-based **Professor Jean-Frederic Colombel MD** who is an internationally recognised clinician and researcher in IBD, having made multiple ground-breaking discoveries in IBD genetics, risk factors and treatments. **Professor Maria Teresa Abreu** is a globally renowned expert in intestinal inflammation, Crohn's disease and ulcerative colitis. Her laboratory focuses on innate immunity, diet, and the role of the microbiome to improve therapies for IBD.

Microba CEO Blake Wills said the new advisory panel was comprised of a group of globally experienced gastroenterologists who would add significant value to the company's mission of achieving important advancements in medicine supporting the development of novel therapies. Professor Colombel, Dr Abreu and Associate Professor Begun will assist us in developing novel treatments to symptoms of IBD. Associate Professor Jake Begun will lead the group as one of Australia's top gastroenterologists, IBD Group Leader at the Mater Research Institute and Chair of the Gastroenterology Society of

Australia's IBD Faculty Executive Committee.

IBD is prevalent worldwide, with 396 cases per 100,000 cases, with around 6.8 million living with IBD around the globe in 2019. Conditions like Inflammatory Bowel Disease, both Crohn's disease and ulcerative colitis will see advances in the treatment regimens.

"Through this international Advisory Panel, we will aim to accelerate the development of our therapeutic candidates and inform future microbiome-based diagnostic tools through Microba's human-first, big-data-driven approach," added Microba CEO Blake Wills.